Glioblastoma multiforme (GBM) is one of the most recalcitrant brain tumors characterized by a tumor microenvironment (TME) that strongly supports GBM growth, aggressiveness, invasiveness, and resistance to therapy. Importantly, a common feature of GBM is the aberrant activation of receptor tyrosine kinases (RTKs) and of their downstream signaling cascade, including the non-receptor tyrosine kinase SRC. SRC is a central downstream intermediate of many RTKs, which triggers the phosphorylation of many substrates, therefore, promoting the regulation of a wide range of different pathways involved in cell survival, adhesion, proliferation, motility, and angiogenesis. In addition to the aforementioned pathways, SRC constitutive activity promotes and sustains inflammation and metabolic reprogramming concurring with TME development, therefore, actively sustaining tumor growth. Here, we aim to provide an updated picture of the molecular pathways that link SRC to these events in GBM. In addition, SRC targeting strategies are discussed in order to highlight strengths and weaknesses of SRC inhibitors in GBM management, focusing our attention on their potentialities in combination with conventional therapeutic approaches (i.e., temozolomide) to ameliorate therapy effectiveness.

Ferri, A., Stagni, V., Barila', D. (2020). Targeting the DNA damage response to overcome cancer drug resistance in glioblastoma. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 21(14).

Targeting the DNA damage response to overcome cancer drug resistance in glioblastoma

Barila', D
2020-07-11

Abstract

Glioblastoma multiforme (GBM) is one of the most recalcitrant brain tumors characterized by a tumor microenvironment (TME) that strongly supports GBM growth, aggressiveness, invasiveness, and resistance to therapy. Importantly, a common feature of GBM is the aberrant activation of receptor tyrosine kinases (RTKs) and of their downstream signaling cascade, including the non-receptor tyrosine kinase SRC. SRC is a central downstream intermediate of many RTKs, which triggers the phosphorylation of many substrates, therefore, promoting the regulation of a wide range of different pathways involved in cell survival, adhesion, proliferation, motility, and angiogenesis. In addition to the aforementioned pathways, SRC constitutive activity promotes and sustains inflammation and metabolic reprogramming concurring with TME development, therefore, actively sustaining tumor growth. Here, we aim to provide an updated picture of the molecular pathways that link SRC to these events in GBM. In addition, SRC targeting strategies are discussed in order to highlight strengths and weaknesses of SRC inhibitors in GBM management, focusing our attention on their potentialities in combination with conventional therapeutic approaches (i.e., temozolomide) to ameliorate therapy effectiveness.
11-lug-2020
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore BIO/18 - GENETICA
English
Con Impact Factor ISI
SRC kinase; cancer therapy; glioblastoma; inflammation; kinase inhibitor; metabolic reprogramming; receptor tyrosine kinase; therapy resistance; tumor microenvironment
Ferri, A., Stagni, V., Barila', D. (2020). Targeting the DNA damage response to overcome cancer drug resistance in glioblastoma. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 21(14).
Ferri, A; Stagni, V; Barila', D
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Ferri_2020_ijms-21-04910-v2.pdf

accesso aperto

Descrizione: Articolo Principale
Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 484.12 kB
Formato Adobe PDF
484.12 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/258228
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 42
  • ???jsp.display-item.citation.isi??? 37
social impact